Patents Examined by Evelyn Huang
-
Patent number: 7115621Abstract: Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents as inhibitors of phosphodiesterase 5 cardiovascular disordersType: GrantFiled: April 2, 2002Date of Patent: October 3, 2006Assignee: Lilly Icos LLCInventors: Jason S. Sawyer, Mark W. Orme, James D. Copp
-
Patent number: 6852716Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to treat diseases or conditions in which ?7 is known to be involved.Type: GrantFiled: February 10, 2003Date of Patent: February 8, 2005Assignee: Pfizer IncInventors: Daniel Patrick Walker, David W. Piotrowski, Eric Jon Jacobsen, Brad A. Acker, Jason K. Myers, Vincent E. Groppi, Jr.
-
Patent number: 6552044Abstract: The present invention relates to substituted indane or dihydroindole compounds of Formula (I) wherein A is an indole. These compounds have high affinity for D4 receptors.Type: GrantFiled: March 21, 2001Date of Patent: April 22, 2003Assignee: H. Lundbeck A/SInventors: Jens Kristian Perregaard, Benny Bang-Andersen, Henrik Pedersen, Ivan Mikkelsen, Robert Dancer
-
Patent number: 6514986Abstract: The invention relates to the new arginine salt forms of S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating antimicrobial infections.Type: GrantFiled: March 9, 2001Date of Patent: February 4, 2003Assignee: Wockhardt LimitedInventors: Noel J. de Souza, Shivkumar Agarwal, Mahesh V. Patel, Satish B. Bhawsar, Rupinder K. Beri, Ravindra D. Yeole, Nitin Shetty
-
Patent number: 6506764Abstract: Compounds of the formula B—X—(CH2)m—CR1R2—(CH2)n—CO—Y (I) have therapeutic utility as inhibitors of metalloproteinases etc.Type: GrantFiled: September 6, 2000Date of Patent: January 14, 2003Assignee: Darwin Discovery, Ltd.Inventors: Andrew Douglas Baxter, David Alan Owen, Duncan Hannah, John Gary Montana
-
Patent number: 6235756Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.Type: GrantFiled: August 22, 1997Date of Patent: May 22, 2001Assignee: The Children's Medical Center CorporationInventor: Robert D'Amato
-
Patent number: 6028085Abstract: Prodrugs of 5HT.sub.Type: GrantFiled: September 30, 1998Date of Patent: February 22, 2000Assignee: SmithKline Beecham plcInventor: Steven Mark Bromidge
-
Patent number: 5985893Abstract: Novel crystal forms of the fluoroquinolone, [S-(R*,S*)]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylam ino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid are disclosed. The forms are characterized by one methanol solvate form, and three anhydrous polymorphic forms, of which, Form III exhibits greatest stability and decreased hygroscopicity.Type: GrantFiled: May 1, 1996Date of Patent: November 16, 1999Assignee: Pharmacia & Upjohn CompanyInventors: Xuanqiang Yu, William C. Schinzer, Michael J. Dunn, Robert Shih-Liang Chao, Dale S. Aldrich, Azhwarsamy Jeganathan, Michael S. Bergren
-
Patent number: 5986098Abstract: A compound of formula (I) to (III) ##STR1## in which the symbols R to R.sub.6 are organic radicals. These compounds can be used as intermediates in the production of a phosphite-HALS product.Type: GrantFiled: July 28, 1997Date of Patent: November 16, 1999Assignee: Clariant Finance (BVI) LimitedInventor: Peter Staniek
-
Patent number: 5961965Abstract: A description is given of water-soluble or water-dispersible polyaspartic acid derivatives, their preparation and their use in cosmetology, especially in hair cosmetology.Type: GrantFiled: July 1, 1997Date of Patent: October 5, 1999Assignee: BASF AktiengesellschaftInventors: Son Nguyen Kim, Axel Sanner, Peter Hossel, Matthias Kroner
-
Patent number: 5958944Abstract: Benzamide compounds of the formula ##STR1## wherein each symbol is as defined in the specification, isomers thereof and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions comprising a therapeutically effective amount of this compound and a pharmaceutically acceptable additive, and therapeutic agents for hypertension, therapeutic agents for angina pectoris, therapeutic agent for asthma, therapeutic agents for renal and peripheral circulatory disturbances and inhibitor of cerebral vasospasm, which comprise this compound. The compound of the present invention has strong smooth muscle relaxing action, and shows hypotensive action and cerebral coronary vasodilating action like conventional calcium antagonists, as well as long-lasting renal and peripheral circulation improving action.Type: GrantFiled: October 17, 1996Date of Patent: September 28, 1999Assignee: Yoshitomi Pharmaceutical Industries, Ltd.Inventors: Masafumi Arita, Tadamasa Saitoh, Masanori Minoguchi, Keiji Yamagami, Hiroyuki Satoh
-
Patent number: 5948791Abstract: The invention relates to novel quinoline derivatives and their therapeutic use against malaria.Type: GrantFiled: November 12, 1996Date of Patent: September 7, 1999Assignee: Hoffmann-La Roche Inc.Inventors: Werner Hofheinz, Raffaello Masciadri
-
Patent number: 5939451Abstract: The present invention is concerned with compounds of formula ##STR1## wherein Z is a substituted indolyl group of formula ##STR2## R.sup.1 is hydrogen, amino, lower alkylamino, lower dialkylamino, lower alkyl, halogen, or trifluoromethyl;R.sup.2 is hydrogen or lower alkyl;R.sup.11 is hydrogen or halogen;R.sup.12 is hydrogen or lower alkyl; anda is a single or double bond;or a pharmaceutically acceptable salt.Type: GrantFiled: June 4, 1997Date of Patent: August 17, 1999Assignee: Hoffmann-la Roche Inc.Inventors: Michael Bos, Claus Riemer, Andrew Sleight
-
Patent number: RE45720Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: February 13, 2014Date of Patent: October 6, 2015Assignees: OXiGENE, Inc., Baylor UniversityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
-
Patent number: RE45839Abstract: Pentakis(dimethylamino) disilane with general formula (1): Si2(NMe2)5Y, where Y is selected from the group comprising H, Cl or an amino group its preparation method and its use to manufacture gate dielectric films or etch-stop dielectric films of SiN or SiON.Type: GrantFiled: April 9, 2014Date of Patent: January 12, 2016Assignee: L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDEInventor: Christian Dussarrat
-
Patent number: RE45907Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: February 13, 2014Date of Patent: March 1, 2016Assignees: OXiGENE, Inc., Baylor UniverswityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
-
Patent number: RE46024Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.Type: GrantFiled: July 1, 2015Date of Patent: June 7, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Nancy-Ellen Haynes, Denis J. Kertesz, Sherrie Lynn Pietranico-Cole, Yimin Qian, Nathan Robert Scott, Sung-Sau So, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley
-
Patent number: RE46095Abstract: Herbicide combinations comprising an effective amount of components (A) and (B), where component (A) is/are one or more herbicides of the formula (I) or salts thereof, in which R1 is H or a group of the formula CZ1Z2Z3, where Z1, Z2 and Z3 are as defined in claim 1, R2 and R3 are each H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl having in each case up to 4 carbon atoms or acyl, R4 is H, (C1-C6)-alkyl or (C1-C6)-alkoxy; R5, R6, R7 and R8 are each H, (C1-C4)-alkyl, (C1-C3)-haloalkyl, halogen, (C1-C3)-alkoxy, (C1-C3)-haloalkoxy or cyano; A is CH2 or O or a direct bond, and the component (B) is one or more herbicides from the group of compounds consisting of (B1) thiencarbazone, tembotrione, SYN-523, pyroxsulam, penoxsulam, SYN-449, (B2) pyrasulfotole, trifloxysulfuron, saflufenacil, aminopyralid, ethofumesate, aminocyclopyrachlor and (B3) pyroxasulfone (KIH-485) are suitable for controlling harmful plants or for regulating the growth of plants.Type: GrantFiled: January 13, 2015Date of Patent: August 9, 2016Assignee: Bayer Intellectual Property GmbHInventors: Erwin Hacker, Martin Hess, Martin Jeffrey Hills, Georg Bonfig-Picard, Thomas Auler
-
Patent number: RE46097Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: GrantFiled: August 23, 2013Date of Patent: August 9, 2016Assignee: Vertex Pharmaceuticals IncorporatedInventors: Gabriel Martinez Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
-
Patent number: RE46151Abstract: The present invention relates to a process for preparing 4,4?-[1-(trifluoromethyl)alkylidene]bis(2,6-diphenylphenols), in particular for preparing 4,4?-[1-(trifluoromethyl)ethylidene]bis(2,6-diphenylphenol), which comprises the self-condensation of cyclohexanone in the presence of a basic catalyst to form tricyclic condensation products, dehydrogenation of the resulting tricyclic condensation products in the presence of a supported transition metal catalyst in the condensed phase to form 2,6-diphenylphenol and reaction of the 2,6-diphenylphenol with a trifluoromethyl ketone. The invention further provides an improved process for preparing 2,6-diphenylphenol by aldol self-condensation of cyclohexanone.Type: GrantFiled: July 2, 2014Date of Patent: September 20, 2016Assignee: BASF SEInventors: Gabriele Gralla, Gunnar Heydrich, Klaus Ebel, Wolfgang Krause